Newsroom 2009

2009 Releases

21/12/2009
Findings of Australian trial of CSL’s Pandemic (H1N1) 2009
CSL Limited, Australia’s leading biopharmaceutical company, announced the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study CSL’s pandemic H1N1 2009 ‘swine' flu vaccine. More.

10/12/2009
Vaccine to treat gum disease on the way
CSL Limited, Australia’s leading biopharmaceutical company, has today announced that a vaccine to treat severe gum disease is being developed in a new collaboration with Sanofi Pasteur, the world’s leading global manufacturer of vaccines. More.

08/12/2009
CHANGES TO CSL SENIOR EXECUTIVE GROUP
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years. More.

14/10/2009
CSL Donates 3 Million doses of Pandemic H1N1 2009 Vaccine to the World Health Organisation (WHO) for use in Low-Income Countries in this Region
CSL Limited, Australia’s leading biopharmaceutical company, has today announced that it is donating 3 million doses of pandemic H1N1 2009 or ‘swine flu’ vaccine to the World Health Organisation for use in priority low-income countries in the South Pacific as well as South East Asia. More.

06/10/2009
Vaccines delivered on time across Australia for largest national immunisation program on record
CSL Biotherapies, a subsidiary of CSL - Australia’s leading biopharmaceutical company, can today confirm that 100% of deliveries of its H1N1 influenza vaccine are being completed on time in all States. More.

18/09/2009
Panvax® H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration
CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, can today confirm that its vaccine against the pandemic (H1N1) 2009 influenza or 'swine flu' has been approved registration for use in people aged 10 years and over. The TGA assesses safety, efficacy and quality when arriving at the decision to register a medical product for use by the general public. More.

11/09/2009
CSL demonstrates robust immune response from single (15mcg) dose of monovalent pandemic (H1N1) 2009 influenza A vaccine in healthy adults
CSL Limited, Australia’s leading biopharmaceutical company, announced today that preliminary data from the first study of its candidate pandemic H1N1 vaccine demonstrated a robust immune response in healthy adults after a single unadjuvanted 15mcg dose. More.

15/07/2009
CSL Backs Key Training Program for Health and Medical Sciences
The Bio21 Cluster today announced sponsorship of its flagship education and training program by CSL Limited. The sponsorship deal will underpin delivery of the Undergraduate Research Opportunities Program (UROP) for the next 3 years. More.

29/06/2009
Trial of Novel H1N1 ‘Swine’ Flu candidate vaccine to take place in Adelaide
CSL Limited, Australia’s leading biopharmaceutical company, will shortly be commencing a clinical trial of a candidate vaccine against Novel H1N1 ‘Swine’ Flu. The trial will be undertaken in partnership with Clinical Research Organisation CMAX and the Royal Adelaide Hospital in South Australia. More.

09/06/2009
CSL and Talecris Biotherapeutics Agree to Terminate Merger Agreement
CSL Limited (ASX: CSL) and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate their merger agreement, announced on August 12, 2008, under which CSL agreed to acquire Talecris for US$3.1 billion in cash. More.

09/06/2009
CSL announces on-market share buyback
CSL Limited (ASX:CSL) today announced its intention to conduct an on-market share buyback of up to 54,863,000 shares1. This represents approximately 9% of the company’s current shares on issue. At an assumed price per share of approximately A$29 (being CSL's last closing price on Friday 5 June), this would represent a total buy back consideration of up to A$1.59 billion. More.

29/05/2009
CSL reaffirms its commitment to supply Australia with Novel Influenza A (H1N1) ‘Swine Flu’ Vaccine
CSL Biotherapies, a subsidiary of CSL Limited, Australia’s leading biopharmaceutical company, welcomes the Rudd Government’s recent announcement of its intention to place an order to supply 10 million Australians with a vaccine against Novel Influenza A (H1N1) or ‘swine flu’. More.

29/05/2009
CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government to Produce Novel Influenza A (H1N1) Vaccine
CSL Limited announced today that its US subsidiary, CSL Biotherapies, Inc., has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form. More.

28/05/2009
CSL Limited responds to FTC announcement
CSL Limited (ASX: CSL) today was informed that the US Federal Trade Commission (“FTC”) will file a complaint in the US Federal District Court to challenge CSL’s proposed acquisition of Talecris Biotherapeutics. More.

25/05/2009
CSL meets with US Federal Trade Commissioners regarding Talecris Acquisition
CSL Limited today announced that Dr Brian McNamee met with the US Federal Trade Commission. More.

07/05/2009
Proposed Acquisition of Talecris Biotherapeutics
CSL Limited has become aware of market and media speculation regarding the proposed acquisition of Talecris Biotherapeutics, Inc. More.

18/02/2009
CSL Half-year Results Announcement for 2008/09
CSL Limited today reported a profit after tax of $502 million for the six months ended 31 December 2008, up 44% when compared to the six months ended 31 December 2007. This included a foreign currency benefit of $26 million and a number of favourable non operational items totalling $44 million in net profit after tax which also boosted the result. Adjusting for currency and the items above, underlying profit growth was 24%. More.

18/01/2009
CSL Limited - Change of Company Secretary
With immediate effect, Mr Edward Bailey is the company secretary of CSL Limited. More.

© 2016 CSL Limited